Effect of Treatment With Peginterferon or Interferon Alfa–2B and Ribavirin on Steatosis in Patients Infected With Hepatitis C

• DOI: 10.1053/jhep.2003.50267
• Publication Date: 2003-06-26T16:37:21Z
• Authors: Thierry Poynard; Vlad Ratziu; John McHutchison; Michael Manns; Zachary Goodman; Stefan Zeuzem; Zobair Younossi; Janice Albrecht
• Keywords: Steatosis; Hepatitis C

It has been suggested that hepatitis C virus (HCV) and especially genotype 3 is associated with steatosis. We assess the effect of treatment peginterferon or interferon alfa-2b ribavirin on analyzed 1,428 naïve patients included in a randomized trial. A single pathologist scored steatosis at baseline 24 weeks after treatment. At baseline, was present 935 (65%), including 175 (83%) 210 versus 760 (62%) 1,218 other genotypes (P <.001). The variables logistic regression were <.001), triglycerides greater than 1.7 mmol/L body mass index 27 <.04), age 40 years septal fibrosis =.007). In 3-infected patients, high viral load lower serum cholesterol. Steatosis sustained response rate, even taking into account factors Among virologic responders, much improved 3, improvement least 1 grade 77%, disappearance 46% compared genotypes, 29%, respectively <.001 both comparisons). low cholesterol corrected by HCV triglycerides, index, age, stage, to conclusion, reduction as well correction